Showing results (71-80 of 192) with videos related to

Sort By:
Pageof 20
The Oncologist|April 12, 2011
Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based surveyMikkael A Sekeres, Jaroslaw P Maciejewski, Alan F List, et al.
British Journal of Haematology|April 29, 2006
Mutations of the myeloid transcription factor CEBPA are not associated with the blast crisis of chronic myeloid leukaemiaThomas Pabst, Erica Stillner, Donna Neuberg, et al.
Blood|April 30, 2008
Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programsDana E Rollison, Nadia Howlader, Martyn T Smith, et al.
Cancer Research|July 5, 2012
HG-829 is a potent noncompetitive inhibitor of the ATP-binding cassette multidrug resistance transporter ABCB1Gisela Caceres, Robert W Robey, Lubomir Sokol, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 18, 2020
SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic SyndromesQing Zhang, Mintallah Haider, Najla H Al Ali, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 15, 2017
A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid LeukemiaAbu-Sayeef Mirza, Jeffrey E Lancet, Kendra Sweet, et al.
Cancer|March 1, 2014
Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromesDavid P Steensma, Rami S Komrokji, Richard M Stone, et al.
Leukemia Research|December 26, 2008
A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemiaJeffrey E Lancet, Maria R Baer, George E Duran, et al.
Leukemia Research|April 17, 2009
Outcome of patients with myelodysplastic syndromes in the Veterans Administration populationRami S Komrokji, Gina M Matacia-Murphy, Najla H Al Ali, et al.
American Journal of Hematology|December 23, 2016
Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experiencePatrick T Griffin, Rami S Komrokji, Kendra Sweet, et al.
Pageof 20